Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Mercell Holding - Conversion to a public limited liability company completed and new name and board of directors registered

Oslo, 23 April 2021: Reference is made to the stock exchange announcement by Mercell Holding AS (the "Company") on 22 April 2021, regarding the annual general meeting of the Company held on the same day. The general meeting inter alia resolved to convert the Company from a private limited liability company to a public limited liability company, and thereby changes its legal name to Mercell Holding ASA, and changes the board of directors. The resolutions of the annual general meeting were registered with the Norwegian Register of Business Enterprises (Nw.: Foretaksregisteret) today, on 23

SRV to build Laakso Joint Hospital in Helsinki

SRV GROUP PLC    INSIDE INFORMATION       23 APRIL 2021     11:00 EET SRV to build Laakso Joint Hospital in Helsinki SRV has been chosen to develop and build Laakso Joint Hospital in Helsinki as an alliance project. The clients are the City of Helsinki and the Helsinki and Uusimaa Hospital District. The project is divided into several development and construction phases, with a total value of approximately EUR 730 million. The project will be entered in SRV's order backlog in accordance with the ordered phases during the years 2021-2028. The project will not tie up SRV's capital and,

Invitation to Q1 2021 webcast

Zalaris ASA will release its first quarter 2021 results on Thursday 29 April 2021.Zalaris will host a webcast for all shareholders and interested parties on 29 April at 08:30 CET. There will be a Q&A session following the management presentation. Link to webcast will be available on ir.zalaris.com. Contact: Gunnar Manum, CFOMobil: +47 95 17 91 90 This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.

BioStock: First approved patent in the US for Iconovo's ICOone

ICOone is Iconovo's single-dose inhaler for simple and cost-effective administration of vaccines and biomolecules. The first US patent has now been approved for the inhaler and thus the company has approved patents for ICOone in Sweden, Europe (EPO), India, and the USA. The patents for ICOone provide, among other things, strong protection for the Covid-19 vaccination opportunities that Iconovo is exploring together with ISR Immune System Regulation.Read the full article at biostock.se:https://www.biostock.se/en/first-approved-patent-in-the-us-for-iconovos-icoone/ This is a press

Kärleksgåvan få i Värmland utnyttjade förra året

Nej, det är inget skämt, det går faktiskt att föra över sin premiepension till sin partner men trots möjligheten är det försvinnande få som idag gör det. I år är det den 31 april som gäller. I Värmland var det 3 kvinnor och 292 män av 44 129 som hade möjligheten i länet som förra året förde över premiepensionen till sin partner. – Att så få ger bort sin premiepension tror jag beror på att man inte känner till att möjligheten finns, säger Trifa Chireh, pensionsekonom på Länsförsäkringar.Under de senaste åren har vi dock sett en ökning med 79 procent men trots det var det under 2020 endast 14

Enfo Group’s interim report Q1 January 1 – March 31, 2021

Enfo Q1/2021: Profitability improved compared to last yearQ1/2021 · Net sales were EUR 30.3 (30.9) million · EBITDA was EUR 3.3 (2.5) million · EBIT was EUR 0.7 (0.2) million · Profit for the period was EUR -0.1 (-2.0) million · Earnings per share were EUR -0.9 (-3.5) · Operating cash flow was EUR 1.6 (2.9) million The numbers in brackets refer to the value in the corresponding period a year earlier, unless otherwise stated. Key figures 1.1.–31.3.2021 1.1.–31.3.2020 1.1.–31.12.2020Net sales, EUR 30.3 30.9

Finnair to accept COVID-19 vaccination certificate as an alternative to negative test result or an immunity certificate when travelling to Finland

Finnair will start accepting a COVID-19 vaccination certificate from the first vaccination dose as an alternative to a negative test result or a certificate of a previous COVID-19 infection, on Finnair flights to Finland from May 11, 2021. In line with the recommendation by the Finnish Institute of Health and Welfare, Finnair has since late January required that all passengers travelling to Finland - excluding transfer passengers - present either a negative test certificate or an immunity/recovery certificate as a prerequisite for boarding. In addition, as of May 11, there is no

Clavister to Deliver 5G Security to Australian Public Safety Network

23 April 2021 – Örnsköldsvik, Sweden – Clavister, a leader in high-performance cybersecurity solutions, today announces that its 5G Security Solution has been selected for a new national mobile broadband network for emergency services in Australia.The first phase of the deployment is a feasibility trial and will be used to test technology that will form the final design of the nationwide public safety mobile broadband (PSMB) capability for emergency situations. The initial order is worth just under 1 MSEK to Clavister, with additional orders to follow on the back of the continuous

Getinge’s heart lung machine HL 40 available for more European hospitals

Inspired by perfusionists, Getinge's HL 40 heart-lung machine is designed to increase safety and ensure maximum uptime in cardiac surgery.   Getinge has been at the forefront of providing state of the art systems heart lung machines for decades, and the HL 40 is no exception. A heart-lung machine permits controlled circulation of oxygenated blood during complex cardiac surgical interventions. “Surgical perfusion allows no room for error and to get end-user feedback our design team have worked closely with perfusionists from the Leeuwarden Medical Center in the Netherlands

The exercise price for the warrants of series TO1 in 2cureX AB has been determined to SEK 13.22 and the subscription period starts April 26, 2021

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE. 2cureX AB (“2cureX” or the “Company”) completed a directed issue of units during the third quarter of 2020. One (1) unit consisted of two (2) newly issued shares and one (1) warrant

Ortoma obtains CE certification for Spine Module

Ortoma has obtained CE certification for its spine module OTS Spine Plan now included in the platform Ortoma Treatment Solution (OTS). The spine module is a pre-operative planning solution for spine surgery. The OTS platform is a surgical system that is assisted by AI (Artificial Intelligence) for improved accuracy, efficiency and surgical outcome.CE certification for OTS Spine Plan is approved by the Notified Body and the CE-marked product is approved for use clinically in Europe. The OTS platform now includes CE marked products for hip replacement surgery and spine surgery.  In addition,

SOTKAMO SILVER AB: PRODUCTION UPDATE AND GUIDANCE 2021

Press release: Stockholm, April 23, 2021 08:45 CET Silver Mine has produced 3 million ounces silver since the production started in 2019. Silver production was 1,00 million ounces in 2019 and 1,58 million ounces in 2020. Silver production during the first quarter of 2021 reached 344 000 ounces and 3 million ounces milestone was achieved in mid-April. The production of the first three weeks of April was 97 000 ounces silver and the Company restates the production guidance for 2021 and expects to produce between 1,45 – 1,75 million ounces of silver in 2021. Stockholm April 23,

Interim report 2021, January 1 – March 31

January - March 2021 Net revenue for the period was SEK 87.7 million (83.7) EBITDA for the period was SEK 8.9 million (5.4) EBITA for the period was SEK 6.9 million (3.4) Profit/loss for the period was SEK 2.5 million (-2.5) Basic earnings per share for the period amounted to SEK 0.02 (-0.02) Orders received for the period totaled SEK 91.7 million (137.3) Operating cash flow for the period was SEK -1.3 million (8.7) CEO’s comments ADDvise entered the first quarter in a strong position, carrying momentum from the fourth quarter of 2020 into the new year with solid

OX2 acquires a 170 MW wind power project in Sweden from Stora Enso

OX2 and Stora Enso have agreed on the purchase of the Hälsingeskogen wind power project in the municipality of Ovanåker, Gävleborg County, Sweden.According to the agreement OX2 acquires 100 percent of the project rights from Stora Enso, which remains the landowner. The wind farm will include 37 wind turbines with a total possible capacity of 170 MW. The estimated annual electricity production amounts to approximately 380 GWh, which corresponds to the average electricity consumption for 72,000 households per year. “Wind power needs to be quadrupled if Sweden is to reach the national goal

C-RAD Web Presentation Interim Report Q1 2021 and AGM speech

Invitation to join the presentation of C-RAD’s first quarter 2021. CEO Tim Thurn will also give his Annual General Meeting speech at this event. The AGM is held on May 7 but without any presence from shareholders or other parties, as communicated previously in the call for the AGM. Date: Thursday May 7, 2021 / kl. 11:00 CET Venue: Online Presentation Topic: C-RAD Interim Report Q1 2021 / AGM speech Procedure: Please register online through the website:   https://us06web.zoom.us/webinar/register/WN_xs_0KzMGT7qEExqblSLzmw After the registration, you will receive a

EMA Grants Accelerated Assessment Procedure for Nefecon for the Treatment of IgA Nephropathy

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that its lead product candidate Nefecon, a novel oral formulation targeting down regulation of IgA1 for the treatment of primary IgA Nephropathy (IgAN), has been granted accelerated assessment procedure by the European Medicine Agency’s (EMA) Committee for Human Medicinal Products (CHMP).Accelerated assessment, which may be granted when the CHMP concludes that the product is of major public health interest and major therapeutic innovation pursuant to Article 14 (9) of Regulation (EC) No 726/

Sivers Semiconductors AB (publ) Annual Report 2020

Sivers Semiconductors AB today publishes the annual report for 2020.The full report can be found at Sivers Semiconductors home page: https://www.sivers-semiconductors.com/annual-reports/ For more information please contact:Anders Storm, CEOTel: +46 70 262 6390E-mail: anders.storm@sivers-semiconductors.comErik Penser Bank is appointed Sivers Semiconductors AB’s Certified Advisor at Nasdaq First North Growth Market.Tel: +46 8 463 80 00 E-mail: certifiedadviser@penser.se

Heliospectra (publ) Interim Report January-March 2021

(GOTHENBURG, Sweden, April 23, 2021)– Heliospectra AB (publ), a world leader in intelligent lighting technology for greenhouse and controlled plant growth environments, presents Interim Report for January-March 2021.Full report is enclosed to this press release and is also uploaded at https://www.heliospectra.com/investor-relations/reports-documents-archive.   SUMMARY OF REPORT SALES AND FINANCIAL PERFORMANCE, JANUARY– MARCHNet sales amounted to KSEK 9,960 (15,200). The operating loss amounted to KSEK -7,302 (-9,058) KSEK, signifying a negative operating margin (neg). The loss

Interim Report January-March 2021 – Pricer AB (publ)

High order intake and net sales growth of 74 percentQ1 2021 ·Net sales amounted to SEK 392.9 M (225.9), an increase of 74 percent compared to the same period last year. ·Operating profit amounted to SEK 17.3 M (7.3), which corresponds to an operating margin of 4.4 percent (3.3). ·Order intake was SEK 443 M (371), an increase of 19 percent compared to the same period last year. ·Order backlog amounted to SEK 550 M (933), of which the majority is expected to be delivered in Q2 and Q3 2021. ·Profit for the period was SEK 17.7 M (14.8). ·Earnings per

Poster with 5-years’ follow-up data presented at the 3rd World Arthroplasty Congress available

Episurf Medical (Nasdaq: EPIS B) today announces that the poster presentation "Clinical results of a patient-specific mini-metal implant for focal cartilage lesions in the knee after 5 years” by Dr. med. Johannes Holz from Orthocentrum, Park-Klinik Manhagen, Hamburg, Germany, et al. which was presented at the 3rd World Arthroplasty Congress, is now available through Episurf Medical’s website. The poster presentation focuses on clinical results from the use of the Episealer® knee implant with a follow-up of up to 5 years (15 patients with 5 years’ results). The poster concludes that “This

Nanologica Interim Report Jan-Mar 2021

Summary of the period FINANCIAL OVERVIEW · Net revenue increased by 54 percent to TSEK 5,622 (3,654) · The operating profit and loss for the period was TSEK -6,768 (-6,032) · Profit and loss after tax for the period was TSEK -7,845 (-6,705) · Earnings per share for the period was SEK -0.28 (-0.40) · Cash and cash equivalents at the end of the period amounted to TSEK 57,069 (1,273) SIGNIFICANT EVENTS DURING THE FIRST QUARTER · Test material from upscaling to large-scale production of silica approved · Scientific advisory board within inhalation formed ·

Lipidor's subsidiary Emollivet takes the next step towards launch and receives funding from Vinnova

Stockholm, Sweden, 23 April 2021 – Sweden's innovation authority Vinnova is investing in Lipidor's subsidiary Emollivet. The funding from Vinnova is for SEK 300,000 and will be used for a project in which Emollivet, through interaction with animal owners and others in the animal health market, will gather data for the upcoming launch.Emollivet develops animal care products based on Lipidor's patented AKVANO technology. The company was funded in 2020 to focus on commercializing animal care products. Since Stina Linge was recruited as CEO last autumn, development in Emollivet has accelerated.

Success for trampolines with well-balanced Swedish quality springs

It´s springtime = time to jump around! With a new outdoor season just around the corner, the timing for a story about trampoline springs could not be better. Lesjöfors customized tension springs for trampolines have contributed to making North Trampoline's Performer a success.The introduction of the premium trampoline Performer has been a success for the Gothenburg-based trampoline specialist North Trampoline. The company ships trampolines to 22 countries in Europe and has just started sales in the US. Australia will follow later this year. North Trampoline expects that sales of the

Exel Composites Plc publishes its Q1 2021 Business Review on 30 April 2021

EXEL COMPOSITES PLC      INVESTOR NEWS      23 APRIL 2021 at 09:00 EETExel Composites Plc publishes its Q1 2021 Business Review on Friday 30 April 2021 at approximately 9:00 EET. A financial results briefing for investors, analysts and journalists will be held the same day at 12:30 EET. The briefing will be hosted by Riku Kytömäki, President and CEO. The briefing will be organized online. Participants are requested to register to the event in advance by sending an email to investor@exelcomposites.com no later than by Wednesday 28 April 2021 at 16:00 EET. A link to join the event will be

There are no items matching the current filter
There are no more items matching the current filter
Back to top